Por que realizar este exame?

In recent years, knowledge of breast cancer has evolved significantly and this condition is currently considered a complex and heterogeneous pathology. Therefore, distinct factors should be considered to determine the patient’s prognosis. Women with breast cancer with early phaseestrogen receptor expression, usually have a good prognosis. However, in this population, about 50% of recurrences occur after five years of diagnosis. An imminent need in the management of breast cancer with estrogen receptor expression is to identify women at increased risk of late recurrence.

O que é o exame?

Prosigna (PAM50) was developed from a PAM50 gene signature that provides the patient’s Risk-Of-Recurrence (ROR) information based on three factors such as tumor size, intrinsic molecular subtype and tumor proliferation status.

Para quem é indicado?

Postmenopausal women who have been mastectomized as a result of breast cancer and who have the following characteristics:
• Positive hormone receptors, negative ganglia, stage I and II breast cancer.
• Positive hormone receptors, ganglia positive (1 – 3.4 or more positive ganglia), stage II or IIIA breast cancer.


nCounter Dx Analysis System


• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Validated in two clinical studies that evaluated more than 2,400 postmenopausal women with early-stage breast cancer.
• Approved by the United States (FDA) and European (EMA) regulatory agencies as a prognostic tool in early breast cancer.
• It provides assessment of the risk of recurrence over up to 10 years and the intrinsic subtype.

Informações Extras

DOCUMENTATION – Available on Extranet for clients:
• Informed Consent.
• Clinical Questionnaire.
• Fasting is not necessary for the test.

Tempo de Entrega
10 working days
Tipo de Amostra
Tumor fragment in paraffin tissue block (see sample preparation instructions)

Assine a nossa newsletter

Cadastre-se para receber novidades sobre nossos exames